CONFIRMED SPEAKERS & CHAIRS INCLUDE:
Alain Vertes, Managing Director, NxR Biotechnologies GmbH
Anker Lundemose, CEO, MISSION Therapeutics Ltd.
Athanasia Anagnostou, Senior Director of Corporate Development, Immunomic Therapeutics, Inc.
Bernd Goergen, Partner, High-Tech-Gruenderfonds Management GmbH
Beverley Carr, VP Business Development Immunoinflammation and Dermatology, GSK
Carlos Buesa, CEO, Oryzon Genomics SA
Carole Nuechterlein, Head of Roche Venture Fund Basel, Roche Venture Fund
Chandra Leo, Portfolio Manager, HBM Partners AG
Charles Bailey, Head of Search & Evaluation, Neurosciences. Global BD & Licensing, Novartis Pharma AG
Chris Maggos, Managing Director, Europe, LifeSci Advisors, LLC
Christian Elling, Managing Partner, Lundbeckfond Emerge
Constantine Chinoporos, CBO, Boston Pharmaceuticals, Inc.
Corinne Danan, EVP, Partnerships BU, HalioDx
Dani Bach, Partner, Life Sciences, IP Group Plc
David Colpman, Director, Colpman Consulting Ltd.
Dragan Grabulovski, CEO & Founder, Grabulovski Consulting Services
Enza Di Modugno, Director, Global Business Development, Roche Partnering
Eric de La Fortelle, Venture Partner, Seventure Partners
Eric Halioua,President & CEO, PDC*line Pharma
Esteban Pombo Villar, CEO, TargImmune Therapeutics AG
Eyal Ballan, Co-founder & CTO, Cannabics Pharmaceuticals, Inc.
Fintan Walton, CEO, PharmaVentures Ltd.
Florence Dal Degan, R&D Innovation Sourcing Director, Novo Nordisk
Florian Schödel, Owner, Philimmune, LLC
Gavin Currie, CEO, Biosceptre (UK) Ltd.
Göran Forsberg, CEO, Cantargia AB
Guillaume Vignon, Senior Vice President Business Development, BeiGene GmbH
Hakan Goker, Senior Investment Director, Merck Ventures
Heinz Lubenau, Chief Operating Officer, Vaximm AG
Hubert Birner, Managing Partner, TVM Capital
Isabel Ferreira, Director, Global Business Development, F. Hoffmann-La Roche Ltd.
Jasper Bos, Vice President and Head of Healthcare, Merck Ventures
Jesus Martin-Garcia, Chief Executive Officer, GeNeuro SA
Jérémie Mariau, CEO, ILTOO Pharma
Ji Li, TBA
Joe Anderson, CEO, Arix Bioscience plc
John Gustofson, Sr. Director, Ventures & Early Stage Collaborations, AbbVie Ventures
John Haurum, CEO, F-star Biotechnology Ltd.
Jonathan Tobin, Life Science Investor, Arix Bioscience plc
Jörg Neermann, Partner, LSP
Juan Pedro Rodríguez Serrate, Associate Analyst - Healthcare, Edison Group
Katya Smirnyagina, Partner, Capricorn Venture Partners
Kia Motesharei, VP, Global Head of BD, Neurology & Immunology, Global BD & Alliance Management, EMD Serono
Laszlo Kiss, Executive Director, Global Neuroscience Lead, External R&D Innovation, Pfizer, Inc.
Laura Corradini, Deputy Global Head BD&L, CNS, Boehringer Ingelheim Pharma GmbH & Co. KG
Laurent Choppe, Managing Partner, Cukierman & Co. Life Sciences
Loïc Vincent, Head Oncology & Immunology Research Partnerships, Takeda Pharmaceuticals International Co.
Louis Brenner, President and Chief Operating Officer, Allena Pharmaceuticals
Lubor Gaal, Head of Licensing and External Innovation, Almirall S.A
Luca Bolliger, VP Corporate Licensing, Recordati S.p.A.
Lynn Durham, CEO, Stalicla SA
Magnus Björsne, CEO, AstraZeneca BioVentureHub
Mark Krul, Partner, Aglaia BioMedical Ventures
Mark Vaeck, CEO, Complix NV
Markus Hosang, General Partner, BioMedPartners AG
Markus Kalousek, Head of Pharma Search & Evaluation, Global BD&L, Novartis Pharma AG
Matthias Müllenbeck, Director Global Oncology L&BD, Global BD & Alliance Management, Merck KGaA
Michael Farley, Director, Valor Management SA
Michael Motz, CBO, NETRIS Pharma
Michael Scherz, Founder & CEO, Metys Pharmaceuticals AG
Michel Wurm, VP, Medical Affairs, Strategy and Business Development, Pharmaleads SA
Ming Wang, President and CEO, Phanes Therapeutics, Inc.
Nathalie ter Wengel, European Head External R&D and Innovation, Pfizer, Inc.
Nawal Ouzren, CEO, Sensorion SA
Nissim Darvish, Senior Managing Director, OrbiMed
Olav Hellebo, CEO, ReNeuron Group plc
Paola Casarosa, Corp. VP of Therapeutic Alliances and Strategic Partnerships, Boehringer Ingelheim International GmbH
Patrick Van Beneden, Partner, Healthcare, Gimv
Rainer Strohmenger, General Partner, Wellington Partners
Remi Droller, Managing Partner, Kurma Partners
Robert Farrell, President & CEO, Kalytera Therapeutics, Inc.
Ronald Kempers, President & CEO, Mymetics Corporation
Ron Lipsky, Investor Relations, MGC Pharma (Aust) Pty Ltd.
Ryan Richardson, Executive Director, Healthcare Investment Banking, JP Morgan Ltd.
Sam Fazeli, Head of European Research, Pharmaceuticals Analyst, Bloomberg Intelligence, Bloomberg
Sarah Cole, Partner, Takeda Ventures, Inc.
Simon Blake, Senior Director, Scientific Licensing for Immunology, Johnson & Johnson
Sofia Ioannidou, Director, Andera Partners
Sten Verland, Partner, Sunstone Capital A/S
Stephan Emmerth, Senior Project Manager Biotech, Business Development Senior Manager, BaseLaunch
Stephanie Léouzon, Partner and Head of Torreya Partners Europe, Torreya Partners (Europe) LLP
Stewart Kay, Director, Business Development, GlaxoSmithKline
Thibaut Roulon, Investment Director, Life Sciences Investments, Bpifrance
Tim Dyer, CEO, Addex Therapeutics Ltd.
Timm Jessen, CEO, Topas Therapeutics GmbH
Timothy Luker, Sen Director, Emerging Technology & Innovation, Business Development, Eli Lilly and Company
Tong Zhang, Managing Director, C-Bridge Capital
Yochi Slonim, Co-Founder, CEO, Anima Biotech Ltd.
William Rice, Chairman, CEO & President , Aptose Biosciences, Inc.